Manuel Díaz Jidy, Antonio Pérez Rodríguez, Roberto Fernández Llanes, Laura Bravo Fariñas, Hilda García Sánchez, Rodrigo Valera Fernández, Luis García Imia, Rafael Fando Calzada, Jorge Menéndez Hernández
{"title":"[Challenge clinical trial for evaluation of a vaccine candidate strain against cholera].","authors":"Manuel Díaz Jidy, Antonio Pérez Rodríguez, Roberto Fernández Llanes, Laura Bravo Fariñas, Hilda García Sánchez, Rodrigo Valera Fernández, Luis García Imia, Rafael Fando Calzada, Jorge Menéndez Hernández","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>live attenuated oral Vibrio cholerae Ol El Tor, Ogawa strain 638 has demonstrated to be well tolerated and immunogenic when administrated orally in studies carried out in healthy volunteers.</p><p><strong>Objectives: </strong>to evaluate the protection against cholera infection in a challenge clinical trial, for the technological and pharmaceutical scale-up of this vaccinal candidate as active ingredient at industrial level.</p><p><strong>Methods: </strong>a total of 21 healthy volunteers were involved in this trial; the vaccine candidate was administered to 12 of them and the remaining nine were given the placebo. Twenty eight days later, all of them received an infective dose of a V. cholerae virulent strain.</p><p><strong>Results: </strong>diarrheas were observed in 7 out of 9 placebos whereas not a single vaccinated volunteer showed diarrheas. More frequent and intense loose stools were found in the placebo volunteers with O-blood group. All volunteers in he placebo group excreted V. cholerae, but only three (25%) out of the 12 vaccinated volunteers did so.</p><p><strong>Conclusion: </strong>in this challenge clinical trial model, the 638 strain proved to protect people against the diarrhea caused by a virulent V. cholerae strain.</p>","PeriodicalId":35915,"journal":{"name":"Revista Cubana de Medicina Tropical","volume":"62 3","pages":"194-9"},"PeriodicalIF":0.0000,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Cubana de Medicina Tropical","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: live attenuated oral Vibrio cholerae Ol El Tor, Ogawa strain 638 has demonstrated to be well tolerated and immunogenic when administrated orally in studies carried out in healthy volunteers.
Objectives: to evaluate the protection against cholera infection in a challenge clinical trial, for the technological and pharmaceutical scale-up of this vaccinal candidate as active ingredient at industrial level.
Methods: a total of 21 healthy volunteers were involved in this trial; the vaccine candidate was administered to 12 of them and the remaining nine were given the placebo. Twenty eight days later, all of them received an infective dose of a V. cholerae virulent strain.
Results: diarrheas were observed in 7 out of 9 placebos whereas not a single vaccinated volunteer showed diarrheas. More frequent and intense loose stools were found in the placebo volunteers with O-blood group. All volunteers in he placebo group excreted V. cholerae, but only three (25%) out of the 12 vaccinated volunteers did so.
Conclusion: in this challenge clinical trial model, the 638 strain proved to protect people against the diarrhea caused by a virulent V. cholerae strain.
在对健康志愿者进行的研究中,口服减毒活霍乱弧菌Ol El Tor, Ogawa菌株638已被证明具有良好的耐受性和免疫原性。目的:在一项挑战性临床试验中评估对霍乱感染的保护作用,以便在工业水平上扩大该候选疫苗作为有效成分的技术和药物规模。方法:21名健康志愿者参与本试验;其中12人接种了候选疫苗,其余9人接种了安慰剂。28天后,所有人都接受了霍乱弧菌毒力菌株的感染剂量。结果:9个安慰剂组中有7个出现腹泻,而没有一个接种疫苗的志愿者出现腹泻。o型血的安慰剂组出现更频繁、更剧烈的稀便。安慰剂组的所有志愿者都排出了霍乱弧菌,但12名接种疫苗的志愿者中只有3人(25%)排出了霍乱弧菌。结论:在这个挑战临床试验模型中,638菌株被证明可以保护人们免受强毒霍乱弧菌菌株引起的腹泻。
期刊介绍:
La Revista Cubana de Medicina Tropical tiene la misión de publicar artículos científicos especializados en medicina tropical, microbiología, parasitología, epidemiología y otras especialidades afines. Se distribuye directamente por el editor a los suscriptores en formato impreso (ISSN 0375-0760). Está dirigida a profesionales y técnicos en el campo de la medicina tropical, microbiología, parasitología y epidemiología. Recibe contribuciones en idioma español, inglés y portugués sin distinción en el país de procedencia.